IFNG and plasma cell myeloma: As far as MM treatment is concerned, it has been shown that IFN-γ induces CD20 expression on multiple myeloma bone marrow plasma cell (BMPC) and B-cells, which may be a facilitating factor for the use of rituximab, which binds to MM BMPCs and may serve as the direction of serotherapy in the chosen group of patients [88].